Prevalence of Hepatitis C Virus Subgenotypes 1a and 1b in Japanese Patients: Ultra-Deep Sequencing Analysis of HCV NS5B Genotype-Specific Region
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Prevalence of Hepatitis C Virus Subgenotypes 1a and 1b in Japanese Patients: Ultra-Deep Sequencing Analysis of HCV NS5B Genotype-Specific Region
Authors
Keywords
Hepatitis C virus, DNA sequence analysis, Polymerase chain reaction, Nucleotide sequencing, Sequence analysis, Japan, Comparative sequence analysis, Phylogenetic analysis
Journal
PLoS One
Volume 8, Issue 9, Pages e73615
Publisher
Public Library of Science (PLoS)
Online
2013-09-18
DOI
10.1371/journal.pone.0073615
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Molecular Pathways: Hepatitis C Virus, CXCL10, and the Inflammatory Road to Liver Cancer
- (2013) J. Brownell et al. CLINICAL CANCER RESEARCH
- Emergence of telaprevir-resistant variants detected by ultra-deep sequencing after triple therapy in patients infected with HCV genotype 1
- (2013) Norio Akuta et al. JOURNAL OF MEDICAL VIROLOGY
- New Virologic Tools for Management of Chronic Hepatitis B and C
- (2012) Stéphane Chevaliez et al. GASTROENTEROLOGY
- Different impact of IL28B polymorphisms on response to peginterferon-α plus ribavirin in HIV-positive patients infected with HCV subtypes 1a or 1b
- (2012) Eugenia Vispo et al. JOURNAL OF CLINICAL VIROLOGY
- Current prospects for interferon-free treatment of hepatitis C in 2012
- (2012) Catherine AM Stedman JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Prevalence of hepatitis C virus genotype 1a in Japan and correlation of mutations in the NS5A region and single-nucleotide polymorphism of interleukin-28B with the response to combination therapy with pegylated-interferon-alpha 2b and ribavirin
- (2012) Kazuhiko Hayashi et al. JOURNAL OF MEDICAL VIROLOGY
- Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1
- (2012) Anna S. Lok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hepatitis C Viral Evolution in Genotype 1 Treatment-Naïve and Treatment-Experienced Patients Receiving Telaprevir-Based Therapy in Clinical Trials
- (2012) Tara L. Kieffer et al. PLoS One
- Evaluation of Persistence of Resistant Variants with Ultra-Deep Pyrosequencing in Chronic Hepatitis C Patients Treated with Telaprevir
- (2012) Xiomara V. Thomas et al. PLoS One
- Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders
- (2011) Kazuaki Chayama et al. HEPATOLOGY
- Directly acting antivirals against hepatitis C virus
- (2011) V. Soriano et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Use of Illumina Deep Sequencing Technology To Differentiate Hepatitis C Virus Variants
- (2011) M. Ninomiya et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection
- (2011) Bruce R. Bacon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genetic Heterogeneity of Hepatitis C Virus in Association with Antiviral Therapy Determined by Ultra-Deep Sequencing
- (2011) Akihiro Nasu et al. PLoS One
- New antiviral therapies for chronic hepatitis C
- (2010) Tatsuo Kanda et al. Hepatology International
- Evolution of hepatitis B genotype C viral quasi-species during hepatitis B e antigen seroconversion
- (2010) Shuang Wu et al. JOURNAL OF HEPATOLOGY
- Development of Hepatitis C Virus Genotyping by Real-Time PCR Based on the NS5B Region
- (2010) Sueli M. Nakatani et al. PLoS One
- Viral Population Estimation Using Pyrosequencing
- (2008) Nicholas Eriksson et al. PLoS Computational Biology
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now